Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies
The DOI matches its Crossref record; 350 of the 352 references it cites were found in a registry or an index.
Abstract
This review brings you up-to-date with the hepatocyte research on: 1) in vitro-in vivo correlations of metabolism and clearance; 2) CYP enzyme induction, regulation, and cross-talk using human hepatocytes and hepatocyte-like cell lines; 3) the function and regulation of hepatic transporters and models used to elucidate their role in drug clearance; 4) mechanisms and examples of idiosyncratic and intrinsic hepatotoxicity; and 5) alternative cell systems to primary human hepatocytes. We also report pharmaceutical perspectives of these topics and compare methods and interpretations for the drug development process.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
1 retracted
Items 201–350 of 350
Tang, C., Lin, J. H., & Lu, A. Y. H. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.003236 · Cited by 89 · cited 1×
“The regulation and the mechanisms of induction of CYPs have been extensively reviewed (Hollenberg, 2002; Lin and Lu, 1998; Tang et al., 2005).”
BackgroundInduction of drug-metabolizing enzymes by xenobiotics
Bock, K. W., Lipp, H., & Bock-Hennig, B. S. (1990) · Xenobiotica · doi:10.3109/00498259009046831 · Cited by 87 · cited 15×
“The downregulation of mrp2 mRNA expression in rat liver upon lipopolysaccharide treatment was not observed in human liver, although protein expression of MRP2 was decreased, indicating species differences in the regulation of this transporter (Elferink et al., 2004).”
BackgroundInfluentialTransporters and Drug Discovery: Why, When, and How
Kim, R. B. (2006) · Molecular Pharmaceutics · doi:10.1021/mp050084o · Cited by 87 · cited 2×
“Although drug transporters are still an emerging area in which an increased knowledge is needed to develop optimal and well validated tools, the pharmaceutical industry is clearly aware of the potential implications of transporters in clinical end points, such as clearance, bioavailability, and drug-drug interactions,…”
BackgroundCarmo, H., Hengstler, J. G., de Boer, D., Ringel, M. T., Remião, F., Carvalho, F. D., Fernandes, E. G. R., dos Reys, L. A., Oesch, F., & Bastos, M. D. L. (2004) · Toxicology · doi:10.1016/j.tox.2004.07.004 · Cited by 86 · cited 1×
“Culture conditions for primary hepatocytes have been optimized to guarantee acceptable levels of drug metabolizing enzymes and responsiveness to enzyme inducers (Carmo et al., 2005; Ringel et al., 2002, 2005).”
MethodSelf-citationDo Preclinical Testing Strategies Help Predict Human Hepatotoxic Potentials?
Peters, T. S. (2005) · Toxicologic Pathology · doi:10.1080/01926230590522121 · Cited by 86
Bjorge, S. M., & Baillie, T. A. (1985) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(85)91014-9 · Cited by 85 · cited 1×
“Both hypoglycin and valproic acid have been shown to form CoA-thioesters in addition to inhibiting β-oxidation (Bjorge and Baillie, 1985; Silva et al., 2001, 2004; Wenz et al., 1981).”
BackgroundInduction of cytochrome-P450 in cryopreserved rat and human hepatocytes
Silva, J. M., Day, S. H., & Nicoll‐Griffith, D. A. (1999) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(99)00090-3 · Cited by 85 · cited 4×
“Silva et al. (1999) had previously reported that the attachment of cryo-preserved human hepatocytes was improved by preincubating the cells to increase the ATP levels in the”
BackgroundMethodInfluentialOrigin of mammalian biliprotein and rearrangement of bilirubin glucuronides in vivo in the rat.
McDonagh, A. F., Palma, L. A., Lauff, J. J., & Wu, T. W. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111492 · Cited by 85 · cited 1×
“The notion that acyl-glucuronides could react chemically with proteins most likely originated from the observation that glucuronides of bilirubin and a number of carboxylic acid compounds formed adducts with albumin in vitro (McDonagh et al., 1984; van Breeman et al., 1985).”
BackgroundGrillo, M. P., Knutson, C. G., Sanders, P. E., Waldon, D. J., Hua, F., & Ware, J. A. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.11.1327 · Cited by 85 · cited 1×
“Several studies have shown that both acyl-glucuronides and acyl-CoAs are able to trans-acylate GSH and proteins (Benet et al., 1993; Bolze et al., 2002; Grillo et al., 2002, 2003; Sidenius et al., 2004) forming thioester-, ester- or amide-bound covalent adducts.”
BackgroundLam, J. L., & Benet, L. Z. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.11.1311 · Cited by 85 · cited 1×
“Lam and Benet (2004) have shown a good agreement between hepatocyte predicted clearance and in vivo clearance whereas for microsomes this prediction is far less (Table 4).”
BackgroundTang, W., Borel, A. G., Fujimiya, T., & Abbott, F. S. (1995) · Chemical Research in Toxicology · doi:10.1021/tx00047a006 · Cited by 84 · cited 3×
“Alternatively, or in addition, these metabolites may act by depleting intramitochondrial GSH or by shifting the mitochondrial redox-state through inhibition of HEPATOCYTE MODELS USED IN DRUG DEVELOPMENT 207 glutathione reductase (Kassahun et al., 1994; Tang et al., 1995).”
BackgroundHargus, S. J., Martin, B. M., George, J. W., & Pohl, L. R. (1995) · Chemical Research in Toxicology · doi:10.1021/tx00050a001 · Cited by 83 · cited 1×
“Further studies by Hargus et al. (1994, 1995) showed that in vivo and in vitro formation of a 110 kDa protein adduct (found to be DPP IV) was also dependent on diclofenac-GlcA formation and could be ameliorated by co-incubation with β-glucuronidase, which hydrolyzes β-1-O-glucuronides.”
BackgroundMeunier, V., Bourrie, M., Julian, B., Marti, E., Guillou, F., Berger, Y., & Fabre, G. (2000) · Xenobiotica · doi:10.1080/004982500406426 · Cited by 83 · cited 2×
“Most researchers in the survey and others (Kostrubsky et al., 1999; Maurel, 1996; Raucy et al., 2004) incubated compounds for only 48 h, whereas others preferred longer periods (Madan et al., 2003; Meunier et al., 2000; Robertson et al., 2000).”
BackgroundSUBSTRATE SPECIFICITY AND KINETIC PROPERTIES OF SEVEN HETEROLOGOUSLY EXPRESSED DOG CYTOCHROMES P450
Shou, M., Norcross, R., Sandig, G., Lu, P., Li, Y., Lin, Y. J., Mei, Q., Rodrigues, A. D., & Rushmore, T. H. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.9.1161 · Cited by 83
Raucy, J. L. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh126 · Cited by 83 · cited 5×
“Koop and Tierney, 1990; Novak and Woodcroft, 2000; Raucy et al., 2004).”
BackgroundInfluentialEXPRESSION AND INDUCTION POTENTIAL OF CYTOCHROMES P450 IN HUMAN CRYOPRESERVED HEPATOCYTES
Roymans, D., Annaert, P., Houdt, J. V., Weygers, A., Noukens, J., Sensenhauser, C., Silva, J., Looveren, C. V., Hendrickx, J., Mannens, G., et al. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.003046 · Cited by 83 · cited 7×
“…human hepatocytes are similar to that in fresh hepatocytes (Li et al., 1999b), there are reports that some batches of cryo-preserved hepatocyte cultures tend to have lower activities than those reported in corresponding fresh hepatocytes (Kafert-Kasting et al., 2006; Roymans et al., 2004, 2005).”
BackgroundInfluentialTreiber, A., Schneiter, R., Delahaye, S., & Clozel, M. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.061614 · Cited by 83 · cited 2×
“Uptake of drugs across the sinusoidal membrane is the first step in hepatobiliary clearance and for some polar drugs with low passive permeability (e.g., pravastatin) this mechanism has been proposed to be the rate determining step (Treiber et al., 2004).”
BackgroundWitherow, L. E., & Houston, J. B. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34868-2 · Cited by 82 · cited 1×
“Cryo-preserved hepatocytes also display the CYP3A4 atypical kinetic phenomena that have been well characterized in microsomes, namely autoactivation, heteroactivation with testosterone and substrate inhibition (Brown et al., 2006; Hallifax et al., 2005; Witherow and Houston 1999).”
BackgroundSelf-citationHydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes
Shishido, S., Koga, H., Harada, M., Kumemura, H., Hanada, S., Taniguchi, E., Kumashiro, R., Ohira, H., Sato, Y., Namba, M., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50014 · Cited by 82 · cited 2×
“(Haskins et al., 2001; Narayanan et al., 2003; Shishido et al., 2003; Tirmenstein et al., 2002).”
BackgroundHewitt, N. J., Bühring, K. U., Dasenbrock, J., Haunschild, J., Ladstetter, B., & Utesch, D. (2001) · PubMed · Cited by 81
Self-citationInduction of Cytochrome P4503A by Taxol in Primary Cultures of Human Hepatocytes
Kostrubsky, V. E., Lewis, L. D., Strom, S. C., Wood, S. G., Schuetz, E. G., Schuetz, J. D., Sinclair, P. R., Wrighton, S. A., & Sinclair, J. F. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.0730 · Cited by 81 · cited 2×
“Retrospective studies suggest that induction observed in vivo can be reproduced in vitro and there are numerous reports of good correlations (Drocourt et al., 2001; Faucette et al., 2004; Hariparsad et al., 2004; Kato et al., 2005; Komoroski et al., 2004; Kostrubsky et al., 1998; Li et al., 1997; PichardGarcia et al.,…”
BackgroundSidhu, J. S., Liu, F., & Omiecinski, C. J. (2003) · Experimental Cell Research · doi:10.1016/j.yexcr.2003.09.001 · Cited by 81 · cited 2×
“In addition, medium formulation (e.g., the addition/omission of serum or specified hormone mixtures) has a significant influence on the morphological development and cell survival of hepatocytes in culture (Pascussi et al., 2000a,b; Sidhu et al., 2004; Turncliff et al., 2004).”
BackgroundRuhnke, M., Nussler, A. K., Ungefroren, H., Hengstler, J. G., Kremer, B., Hoeckh, W., Gottwald, T. P., Heeckt, P. F., & Fändrich, F. (2005) · Transplantation · doi:10.1097/01.tp.0000157362.91322.82 · Cited by 80 · cited 4×
“Although some activities of xenobiotic metabolizing enzymes were detectable, CYP3A4 activities were much lower in NeoHep cells compared to primary hepatocytes (Ruhnke et al., 2005a), probably due to a lack of expression of PXR.”
BackgroundMethodInfluentialSelf-citationBolze, S., Bromet, N., Gay-Feutry, C., Massière, F., Boulieu, R., & Hulot, T. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.4.404 · Cited by 79 · cited 1×
“Several studies have shown that both acyl-glucuronides and acyl-CoAs are able to trans-acylate GSH and proteins (Benet et al., 1993; Bolze et al., 2002; Grillo et al., 2002, 2003; Sidenius et al., 2004) forming thioester-, ester- or amide-bound covalent adducts.”
BackgroundUwai, Y., Saito, H., & Inui, K. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00837-2 · Cited by 79 · cited 4×
“identify compounds that have a transporter-dependent uptake for example, cyclosporine A for OATPs, quinidine for OCTs, and glibenclamide for OATPs and OATs (Arndt et al., 2001; Sahi, 2005; Shitara et al., 2002; Uwai et al., 2000).”
MethodInfluentialGrant, M. H., Melvin, M. A. L., Shaw, P. M., Melvin, W. T., & Burke, M. D. (1985) · FEBS Letters · doi:10.1016/0014-5793(85)80436-1 · Cited by 79 · cited 1×
“The low abundance of CYP mRNAs at 72 h indicates a limited metabolic capacity in serum-containing collagen conventional cultures over extended periods of time, making more suitable for short-term applications (Grant et al., 1985).”
BackgroundKato, M., Chiba, K., Horikawa, M., & Sugiyama, Y. (2005) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.20.236 · Cited by 79 · cited 2×
“Retrospective studies suggest that induction observed in vivo can be reproduced in vitro and there are numerous reports of good correlations (Drocourt et al., 2001; Faucette et al., 2004; Hariparsad et al., 2004; Kato et al., 2005; Komoroski et al., 2004; Kostrubsky et al., 1998; Li et al., 1997; PichardGarcia et al.,…”
BackgroundUse of long-term cultures of human hepatocytes to study cytochrome P450 gene expression
Pichard‐Garcia, L., Gerbal‐Chaloin, S., Ferrini, J.-B., Fabre, J., & Maurel, P. (2002) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(02)57689-8 · Cited by 78 · cited 2×
“This underlines the importance of culturing human hepatocytes in the presence of appropriate cocktails of inducers to maintain a HEPATOCYTE MODELS USED IN DRUG DEVELOPMENT 171 metabolic competence in these cells (Pichard-Garcia et al., 2002).”
BackgroundSelf-citationRoymans, D., Looveren, C. V., Leone, A. M., Parker, J. B., McMillian, M., Johnson, M. D., Koganti, A., Gilissen, R., Silber, P. M., Mannens, G., et al. (2003) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.09.022 · Cited by 78 · cited 3×
“Interestingly, in an earlier report by Roymans et al. (2004), the relative potency of three glitazone drugs, troglitazone, rosiglitazone, and plioglitazone, in inducing CYP1A2 and CY3A4 in cryo-preserved human hepatocytes reflected that already seen in fresh hepatocyte studies.”
BackgroundEVALUATION OF TIME-DEPENDENT INACTIVATION OF CYP3A IN CRYOPRESERVED HUMAN HEPATOCYTES
Zhao, P., Kunze, K. L., & Lee, C. A. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002832 · Cited by 78 · cited 2×
“, 2001) or even hepatocytes (Zhao et al., 2005).”
BackgroundUse of hepatocyte cultures for the study of hepatotoxic compounds
Guillouzo, A., Morel, F., Langouët, S., Mahéo, K., & Rissel, M. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80499-0 · Cited by 76 · cited 2×
“Human hepatocytes once isolated, are placed in chemically defined culture conditions where they express typical hepatic biochemical functions and contain the entire hepatic drug-metabolizing enzyme system in an integrated form providing an in vitro model that is a very useful tool for anticipating drug metabolism and…”
BackgroundSelf-citationEffect of human liver source on the functionality of isolated hepatocytes and liver slices.
Olinga, P., Merema, M. T., Hof, I. H., de Jong, K. P., Slooff, M. J. H., Meijer, D. K. F., & Groothuis, G. M. (1998) · PubMed · Cited by 75
Self-citationHewitt, N. J., de Kanter, R., & LeCluyse, E. L. (2006) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.12.009 · Cited by 75
Self-citationLam, C., Chan, A. O. O., Ho, P., Ng, I. O., Lo, C. M., Liu, C.-L., Poon, R. T. P., & Fan, S.-T. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01912.x · Cited by 75 · cited 2×
“Reports by Wilson et al. (2003) suggest that this may be lower, although the liver samples used in these studies were from liver tumor patients, which are known to exhibit hepatomegaly (Lam et al., 2004) and such may have lower hepatocellularities than nondiseased tissue.”
BackgroundOhno, M., Yamaguchi, I., Ito, T., Saiki, K., Yamamoto, I., & Azuma, J. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050708 · Cited by 74 · cited 1×
“This model is supported by the observation that the circadian variation of hepatic CYP3A4 in man correlates with cortisol in its circadian fluctuation (Ohno et al., 2000; Pascussi et al., 2003).”
BackgroundKassahun, K., Hu, P. L., Grillo, M. P., Davis, M. R., Jin, L., & Baillie, T. A. (1994) · Chemico-Biological Interactions · doi:10.1016/0009-2797(94)90014-0 · Cited by 74 · cited 2×
“Alternatively, or in addition, these metabolites may act by depleting intramitochondrial GSH or by shifting the mitochondrial redox-state through inhibition of HEPATOCYTE MODELS USED IN DRUG DEVELOPMENT 207 glutathione reductase (Kassahun et al., 1994; Tang et al., 1995).”
BackgroundLeCluyse, E., Bullock, P., Madan, A., Carroll, K., & Parkinson, A. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15241-5 · Cited by 74
Self-citationAllen, S. W., Mueller, L., Williams, S. N., Quattrochi, L. C., & Raucy, J. L. (2001) · PubMed · Cited by 74
Li, A. P., Hartman, Lu, Collins, & strong (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00081.x · Cited by 73 · cited 4×
“Selective induction of SULT has been demonstrated in human hepatocytes, the consequence of such induction can lead to failure of the therapeutic efficacy of the compound (Li et al., 1999a).”
BackgroundMethodInfluentialSelf-citationComparative Effects of Fibrates on Drug Metabolizing Enzymes in Human Hepatocytes
Prueksaritanont, T., Richards, K. M., Qiu, Y., Strong-Basalyga, K., Miller, A. R., Li, C., Eisenhandler, R., & Carlini, E. J. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9011-5 · Cited by 73 · cited 1×
“UGT1A1 is induced by fibric acid derivatives in human hepatocytes (although not via PXR), suggesting that these drugs have a potential to cause various pharmacokinetic drug interactions in vivo (Prueksaritanont et al., 2005).”
BackgroundEngtrakul, J. J., Foti, R., Strelevitz, T. J., & Fisher, M. B. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.005058 · Cited by 73 · cited 3×
“This has recently been exemplified by a study on AZT (Engtrakul et al., 2005) where it was found that hepatocytes gave a good prediction of in vivo clearance whereas microsomes, despite extensive work to optimize conditions, would only provide a clearance value one-tenth of the hepatocyte value (Table 4).”
MethodInfluentialLu, A. Y. H. (1998) · PubMed · Cited by 73
The Role of Conjugation in Hepatotoxicity of Troglitazone in Human and Porcine Hepatocyte Cultures
Kostrubsky, V. E., Sinclair, J. F., Ramachandran, V., Venkataramanan, R., Wen, Y. H., Kindt, K., Galchev, G., Rose, R., Sinz, S., & Strom, S. C. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)13660-4 · Cited by 72 · cited 4×
“…is bioactivated to the sulfate and quinine (which is found to have some toxic effects, albeit lower than troglitazone itself (Yamamoto et al., 2001)) but detoxified by glucuronidation, as noted using pig hepatocytes which predominantly glucuronidate troglitazone (Kostrubsky et al., 2000).”
BackgroundInfluentialFella, K., Glückmann, M., Hellmann, J., Karas, M., Kramer, P.-J., & Kröger, M. (2005) · PROTEOMICS · doi:10.1002/pmic.200401067 · Cited by 71 · cited 2×
“The first successful applications have been identification of potential markers of toxicity using a proteomics approach alone (Fella et al., 2005), or using proteomics in combination with other ‘omics-technologies (Ruepp et al.”
MethodMetabolism of aceclofenac in humans.
Bort, R., Ponsoda, X., Carrasco, E., Gómez‐Lechón, M. J., & Castell, J. V. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07441-0 · Cited by 71 · cited 3×
“Several studies show that primary hepatocyte cultures are a good model to qualitatively predict the in vivo metabolic profile of a drug (Bort et al., 1996a,b; Hewittt et al., 2001; Ponsoda et al., 2001; Salonen et al., 2003).”
BackgroundSelf-citationAnnaert, P., & Brouwer, K. L. R. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001669 · Cited by 71
BAYLISS, M. K. (1999) · Xenobiotica · doi:10.1080/004982599238650 · Cited by 70 · cited 4×
“Almost all predictions for human clearance are made using 120 million cells/g liver weight (Andersson et al., 2001; Bachmann et al., 2003; Bayliss et al., 1999; Davies and Morris 1993; Fisher et al., 2002; Iwatsubo et al., 1997; Lave et al., 1997; McGinnity et al., 2004; Naritomi et al., 2003; Salonen et al., 2003; So…”
BackgroundInfluentialSahi, J., Milad, M. A., Zheng, X., Rose, K., Wang, H., Stilgenbauer, L., Gilbert, D., Jolley, S. L., Stern, R. H., & LeCluyse, E. L. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.050526 · Cited by 70 · cited 2×
“Retrospective studies suggest that induction observed in vivo can be reproduced in vitro and there are numerous reports of good correlations (Drocourt et al., 2001; Faucette et al., 2004; Hariparsad et al., 2004; Kato et al., 2005; Komoroski et al., 2004; Kostrubsky et al., 1998; Li et al., 1997; PichardGarcia et al.,…”
BackgroundSelf-citationCultured human adult hepatocytes: a new model for drug metabolism studies
Bégué, J., Bigot, J. F. L., Guguen‐Guillouzo, C., Kiechel, J. R., & Guillouzo, A. (1983) · Biochemical Pharmacology · doi:10.1016/0006-2952(83)90341-6 · Cited by 69 · cited 1×
“Neither of these two types of criticism are applicable to hepatocytes, therefore, they have a clear advantage over subcellular fractions (Bayliss et al., 1999; Begue et al., 1983; Lave et al., 1997).”
BackgroundSelf-citationCharacterization of regulatory mechanisms and states of human organic cation transporter 2
Biermann, J., Lang, D., Gorboulev, V., Koepsell, H., Sinđić, A., Schröter, R., Žvirblienė, A., Pavenstädt, H. J., Schlatter, E., & Ciarimboli, G. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00622.2005 · Cited by 69 · cited 3×
“…cultures (either as a conventional monolayer with no overlay or as a sandwich culture (Liu et al., 1999; Rose et al., 2006)), primary hepatocyte suspensions (Reichard et al., 2003; Sandker et al., 1994) and transfected cell lines expressing defined transporters (Biermann et al., 2006; Sahi, 2005).”
BackgroundElectrophilic reactions of acyl-linked glucuronides. Formation of clofibrate mercapturate in humans.
Stogniew, M., & Fenselau, C. (1982) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07943-7 · Cited by 68 · cited 1×
“Recently, interest has turned to acyl-CoAs as chemically reactive metabolites, although speculations on sources of reactive metabolites other than acyl-glucuronides already arose in the 1980s (Drew and Knights, 1985; Hertz and Bar-Tana, 1998; Stogniew and Fenselau, 1982).”
BackgroundGriffin, S. J., & Houston, J. B. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.33.1.115 · Cited by 68 · cited 1×
“The clearance (CLint) of a number of compounds was compared in freshly isolated rat hepatocyte suspensions and cultures (Griffin and Houston, 2005).”
BackgroundSelf-citationDilger, K. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.106872 · Cited by 66 · cited 1×
“Like inhibition, induction results in altered pharmacokinetics or pharmacodynamics (Dilger et al., 2000; Kolars et al., 1991).”
BackgroundHaskins, J. R., Rowse, P. E., Rahbari, R., & de la Iglesia, F. (2001) · Archives of Toxicology · doi:10.1007/s002040100251 · Cited by 66 · cited 2×
“(Haskins et al., 2001; Narayanan et al., 2003; Shishido et al., 2003; Tirmenstein et al., 2002).”
BackgroundSalonen, J. S., Nyman, L. M., Boobis, A. R., Edwards, R. J., Watts, P. S., Lake, B. G., Price, R. J., Renwick, A. B., Gómez‐Lechón, M. J., Castell, J. V., et al. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.9.1093 · Cited by 66 · cited 5×
“Almost all predictions for human clearance are made using 120 million cells/g liver weight (Andersson et al., 2001; Bachmann et al., 2003; Bayliss et al., 1999; Davies and Morris 1993; Fisher et al., 2002; Iwatsubo et al., 1997; Lave et al., 1997; McGinnity et al., 2004; Naritomi et al., 2003; Salonen et al., 2003; So…”
BackgroundMethodInfluentialSelf-citationIn Vitro Reactivity of Carboxylic Acid-CoA Thioesters with Glutathione
Sidenius, U., Skonberg, C., Olsen, J., & Hansen, S. H. (2003) · Chemical Research in Toxicology · doi:10.1021/tx034127o · Cited by 65 · cited 1×
“Several studies have shown that both acyl-glucuronides and acyl-CoAs are able to trans-acylate GSH and proteins (Benet et al., 1993; Bolze et al., 2002; Grillo et al., 2002, 2003; Sidenius et al., 2004) forming thioester-, ester- or amide-bound covalent adducts.”
BackgroundSelf-citationNarayanan, P. K., Hart, T., Elcock, F. J., Zhang, C., Hahn, L., McFarland, D., Schwartz, L. W., Morgan, D., & Bugelski, P. J. (2003) · Cytometry Part A · doi:10.1002/cyto.a.10011 · Cited by 65 · cited 1×
“…with others who reported structural and functional abnormality of mitochondria in hepatoma cell lines and isolated hepatocytes treated with troglitazone HEPATOCYTE MODELS USED IN DRUG DEVELOPMENT 205 (Haskins et al., 2001; Narayanan et al., 2003; Shishido et al., 2003; Tirmenstein et al., 2002).”
BackgroundEmoto, C., Yamazaki, H., Yamasaki, S., Shimada, N., Nakajima, M., & Yokoi, T. (2000) · Xenobiotica · doi:10.1080/00498250050200104 · Cited by 65
Blanchard, N., Hewitt, N. J., Silber, P., Jones, H., Coassolo, P., & Lave, T. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.5.0008 · Cited by 64 · cited 4×
“Shibata et al. (2002) suggested that hepatocytes should be pooled to give an “average donor”, however, an advantage of single donor incubations is that clearance may be linked to enzyme characteristics, as was demonstrated with four of the six compounds tested by Blanchard et al. (2006).”
BackgroundMethodResultInfluentialSelf-citationSu, T., & Waxman, D. J. (2004) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2004.02.008 · Cited by 64 · cited 4×
“…of restoring normal CYP2B1, CYP3A1, HEPATOCYTE MODELS USED IN DRUG DEVELOPMENT 209 CYP4A1, HNF4, and CEBPα (a cyclic AMP response element-binding protein) levels; it also decreased initially elevated HNF6 expression and maintained constant levels of HNF3α, HNF3β, and CEBPβ (Su and Waxman, 2004).”
BackgroundInfluentialThe applicability of rat and human liver slices to the study of mechanisms of hepatic drug uptake
Olinga, P., Hof, I. H., Merema, M. T., Smit, M., de Jager, M. H., Swart, P. J., Slooff, M. J. H., Meijer, D. K. F., & Groothuis, G. M. M. (2001) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(01)00127-7 · Cited by 64 · cited 4×
“Initial experiments aimed to optimize methods using fresh rat hepatocytes and subsequent assays were successfully extended to fresh and cryo-preserved human hepatocytes (Liu et al., 1999; Olinga et al., 2001; Sandker et al., 1994; Yamashiro et al., 2006).”
BackgroundMethodInfluentialSelf-citationInduction and drug development
Smith, D. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00107-x · Cited by 63 · cited 2×
“The interpretation of the in vivo relevance in man of in vitro induction data poses a number of problems since many compounds that have been tested for their induction potential do not advance to clinical studies (Smith, 2000).”
BackgroundExpression and Characterization of Canine Cytochrome P450 2D15
Roussel, F., Duignan, D. B., Lawton, M. P., Obach, R. S., Strick, C. A., & Tweedie, D. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.0801 · Cited by 63
Characterization of transport in isolated human hepatocytes
Sandker, G. W., Weert, B., Olinga, P., Wolters, H., Slooff, M. J. H., Meijer, D. K. F., & Groothuis, G. M. M. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90255-0 · Cited by 62 · cited 3×
“…cultures (either as a conventional monolayer with no overlay or as a sandwich culture (Liu et al., 1999; Rose et al., 2006)), primary hepatocyte suspensions (Reichard et al., 2003; Sandker et al., 1994) and transfected cell lines expressing defined transporters (Biermann et al., 2006; Sahi, 2005).”
BackgroundMethodSelf-citationLi, A. P., & Jurima‐Romet, M. (1997) · Cell Biology and Toxicology · doi:10.1023/a:1007451911843 · Cited by 62
Self-citationIn Vitro Methods to Study Chemically-Induced Hepatotoxicity: A Literature Review
Farkas, D., & Tannenbaum, S. (2005) · Current Drug Metabolism · doi:10.2174/1389200053586118 · Cited by 62 · cited 1×
“When isolated and handled appropriately they express a broad range of metabolizing enzyme activities, hepatic transporters, and other differentiated functions (Dambach et al., 2005; Farkas and Tannenbaum, 2005; Guillouzo, 1998, O’Brien et al., 2004, Gómezlechón et al., 2004,).”
BackgroundTerry, C., Dhawan, A., Mitry, R. R., Lehec, S. C., & Hughes, R. D. (2006) · Liver Transplantation · doi:10.1002/lt.20683 · Cited by 62 · cited 1×
“Indeed, some have shown that attachment of both cryo-preserved rat and human hepatocytes can be improved by preincubating the fresh hepatocytes with fructose and/or alpha-lipoic acid prior to freezing (Terry et al., 2006).”
BackgroundWang, Y., Ripperger, J., Fey, G. H., Samols, D., Kordula, T., Wetzler, M., Van Etten, R. A., & Baumann, H. (1999) · Hepatology · doi:10.1002/hep.510300318 · Cited by 62 · cited 1×
“An example of this is the IL-6-induced time-dependent activation (phosphorylation) of STAT3 in primary mouse hepatocytes (Wang et al., 1999).”
BackgroundRole of CYP3A4 in the regulation of the aryl hydrocarbon receptor by omeprazole sulphide
Gerbal‐Chaloin, S., Pichard‐Garcia, L., Fabre, J., Cunha, A. S., Poellinger, L., Maurel, P., & Daujat‐Chavanieu, M. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2005.07.007 · Cited by 61 · cited 2×
“However, Gerbal-Chaloin et al. (2006) have demonstrated that the complexity of crosstalk between PXR/CYP3A4 and Ahr should not be underestimated.”
BackgroundSelf-citationThe Effects of Cryopreservation on Human Hepatocytes Obtained from Different Sources of Liver Tissue
Terry, C., Mitry, R. R., Lehec, S. C., Muiesan, P., Rela, M., Heaton, N. D., Hughes, R. D., & Dhawan, A. (2005) · Cell Transplantation · doi:10.3727/000000005783982765 · Cited by 60 · cited 1×
“Terry et al. (2005) reported a difference in the attachment efficiency of cryo-preserved hepatocytes originating from whole liver and from healthy sections of liver where the other part was used for transplantation however, the post-thaw viabilities of both were very low (36% and 47%, respectively).”
BackgroundSzabó, K., Bakos, É., Welker, E., Müller, M., Goodfellow, H. R., Higgins, C. F., Váradi, A., & Sarkadi, B. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.37.23165 · Cited by 60 · cited 1×
“The latter is based on a transporter protein mutation resulting in additional phosphorylation sites to increase the ATPase activity (Szabo et al., 1997).”
BackgroundIdentification of glutathione conjugates of troglitazone in human hepatocytes
Prabhu, S., Fackett, A., Lloyd, S., McClellan, H., Terrell, C. M., Silber, P. M., & Li, A. P. (2002) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(02)00056-x · Cited by 59 · cited 1×
“Cryo-preserved human hepatocytes form two GSH-conjugates (Prabhu et al., 2002).”
Self-citationStudies on the Reactivity of Clofibryl-S-Acyl-CoA Thioester with Glutathione in Vitro
Grillo, M. P., & Benet, L. Z. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.1.55 · Cited by 59
Blanchard, N., Richert, L., Notter, B., Delobel, F., David, P., Coassolo, P., & Lavé, T. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.07.007 · Cited by 59 · cited 2×
“Blanchard et al. (2004) also compared the clearance of compounds in suspensions and cultures in both rat and human hepatocytes (Blanchard et al.”
ResultLetter, E. D. D., Bouche, M., Bocxlaer, J. V., Lambert, W., & Piette, M. (2004) · Forensic Science International · doi:10.1016/j.forsciint.2003.12.015 · Cited by 59 · cited 1×
“Some individuals have died after ingestion of a single tablet, while others have survived after high doses of MDMA, suffering only mild sympathetic symptoms such as tachycardia and hypertension (de Letter et al., 2004; O’Donohoe et al., 1998).”
BackgroundGriffin, S. J., & Houston, J. B. (2005) · PubMed · doi:10.1124/dmd.33.1 · Cited by 58
Self-citationTurncliff, R. Z., Meier, P. J., & Brouwer, K. L. R. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.8.834 · Cited by 57 · cited 2×
“In addition, medium formulation (e.g., the addition/omission of serum or specified hormone mixtures) has a significant influence on the morphological development and cell survival of hepatocytes in culture (Pascussi et al., 2000a,b; Sidhu et al., 2004; Turncliff et al., 2004).”
BackgroundHallifax, D., Rawden, H. C., Hakooz, N., & Houston, J. B. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.005389 · Cited by 57 · cited 2×
“However Km values tend to be lower in cryo-preserved hepatocytes than in microsomes and as a result the particular clearance value obtained for a drug using hepatocytes may be slightly higher or similar to microsomes (Brown et al., 2006; Hallifax et al., 2005).”
BackgroundResultSelf-citationRichert, L., Alexandre, E., Lloyd, T., Orr, S., Viollon‐Abadie, C., Patel, R., Kingston, S., Berry, D., Dennison, A., Heyd, B., et al. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.0930.x · Cited by 56 · cited 1×
“While for rat hepatocytes, this is usually not a very big issue because, unlike human hepatocytes, hepatocytes from a single rat strain should not vary significantly (Olinga et al., 1998a; Richert et al., 2004).”
BackgroundHallifax, D., & Houston, J. B. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.010413 · Cited by 56 · cited 2×
“Kp values of several hundred are observed for both imipramine and propranolol, and probably many other lipophilic basic drugs (Hallifax and Houston, 2006).”
BackgroundSelf-citationApplication of Scintillation Proximity Assay in Drug Discovery
Wu, S., & Liu, B. (2005) · BioDrugs · doi:10.2165/00063030-200519060-00005 · Cited by 54
Viability and drug metabolism capacity of alginate-entrapped hepatocytes after cryopreservation
Rialland, L., Guyomard, C., Scotté, M., Chesné, C., & Guillouzo, A. (2000) · Cell Biology and Toxicology · doi:10.1023/a:1007690009927 · Cited by 53
Self-citationCryopreservation of Porcine Hepatocyte Cultures
Koebe, H. G., Dähnhardt, C., Müller-Höcker, J., WAGNER, H., & Schildberg, F. W. (1996) · Cryobiology · doi:10.1006/cryo.1996.0013 · Cited by 53 · cited 1×
“This is a method that was previously used by Koebe et al. (1996, 1999) to cryo-preserve porcine hepatocytes but they used a double gel sandwich culture.”
MethodSteady‐State Pharmacokinetics and Dose Proportionality of Troglitazone and Its Metabolites
Loi, C., Alvey, C. W., Vassos, A. B., Randinitis, E. J., Sedman, A. J., & Koup, J. R. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922008533 · Cited by 53 · cited 1×
“In humans, troglitazone is predominantly conjugated with sulfate (70% of all metabolites (Loi et al., 1999a,b) and only 3% of orally administered troglitazone is excreted unchanged in the urine.”
BackgroundAndersson, T. B., Sjöberg, H., Hoffmann, K., Boobis, A. R., Watts, P. S., Edwards, R. J., Lake, B. G., Price, R. J., Renwick, A. B., Gómez-Lechón, M. J., et al. (2001) · PubMed · Cited by 50
Self-citationRole of hepatocyte nuclear factor 3γ in the expression of human CYP2C genes
Bort, R., Gómez‐Lechón, M. J., Castell, J. V., & Jover, R. (2004) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2004.03.032 · Cited by 48 · cited 3×
“Gene reporter experiments with proximal promoters showed that HNF-3γ transactivated CYP2C8, CYP2C9, and CYP2C19 but not CYP2C18.”
BackgroundSelf-citationBeerheide, W., von Mach, M.-A., Ringel, M. T., Fleckenstein, C., Schumann, S., Renzing, N., Hildebrandt, A., Brenner, W., Jensen, O., Gebhard, S., et al. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00596-x · Cited by 48 · cited 1×
“Numerous articles have reported the generation of hepatocyte-like cells from different types of extrahepatic stem or precursor cells (Beerheide et al., 2002; Hengstler et al., HEPATOCYTE MODELS USED IN DRUG DEVELOPMENT 211 2005; Nussler et al., 2006).”
BackgroundSelf-citationComparison of clearance predictions using primary cultures and suspensions of human hepatocytes
Blanchard, N., Alexandre, E., Abadie, C., Lavé, T., Heyd, B., Mantion, G., Jaeck, D., Richert, L., & Coassolo, P. (2005) · Xenobiotica · doi:10.1080/00498250400021820 · Cited by 48 · cited 2×
“(2004) also compared the clearance of compounds in suspensions and cultures in both rat and human hepatocytes (Blanchard et al., 2005).”
BackgroundResultHepatocytes cultured in alginate microspheres: an optimized technique to study enzyme induction
Ringel, M. T., von Mach, M.-A., Santos, R., Feilen, P. J., Brulport, M., Hermes, M., Bauer, A., Schormann, W., Tanner, B., Schön, M. R., et al. (2004) · Toxicology · doi:10.1016/j.tox.2004.07.017 · Cited by 47 · cited 1×
“Culture conditions for primary hepatocytes have been optimized to guarantee acceptable levels of drug metabolizing enzymes and responsiveness to enzyme inducers (Carmo et al., 2005; Ringel et al., 2002, 2005).”
MethodSelf-citationPrediction of in vivo hepatic clearance from in vitro data using cryopreserved human hepatocytes
Bachmann, K. A., Byers, J. P., & Ghosh, R. (2003) · Xenobiotica · doi:10.1080/0049825031000076177 · Cited by 46 · cited 2×
“Almost all predictions for human clearance are made using 120 million cells/g liver weight (Andersson et al., 2001; Bachmann et al., 2003; Bayliss et al., 1999; Davies and Morris 1993; Fisher et al., 2002; Iwatsubo et al., 1997; Lave et al., 1997; McGinnity et al., 2004; Naritomi et al., 2003; Salonen et al., 2003; So…”
BackgroundNomeir, A. A., Ruegg, C., Shoemaker, M., Favreau, L. V., Palamanda, J. R., Silber, P., & Lin, C. (2001) · PubMed · Cited by 46
In vitro Investigation of the Molecular Mechanisms of Hepatotoxicity
Castell, J. V., Gómez-Lechón, M. J., Ponsoda, X., & Bort, R. (1997) · Archives of toxicology. Supplement · doi:10.1007/978-3-642-60682-3_29 · Cited by 45 · cited 2×
“Concentrations to which cells are exposed in such cell metabolism studies should not cause perceptible cell death (Castell et al., 1997b).”
BackgroundSelf-citationSynthesis and Intramitochondrial Levels of Valproyl-Coenzyme A Metabolites
Silva, M. F. B., Ruiter, J. P. N., IJlst, L., Allers, P., ten Brink, H. J., Jakobs, C., Durán, M., de Almeida, I. T., & Wanders, R. J. A. (2001) · Analytical Biochemistry · doi:10.1006/abio.2000.4947 · Cited by 45 · cited 1×
“Both hypoglycin and valproic acid have been shown to form CoA-thioesters in addition to inhibiting β-oxidation (Bjorge and Baillie, 1985; Silva et al., 2001, 2004; Wenz et al., 1981).”
BackgroundCastell, J. V., Hernández, D., Am, G.-F., Guillén, I., Donato, M. T., & Gómez-Lechón, M. (1997) · Gene Therapy · doi:10.1038/sj.gt.3300416 · Cited by 44 · cited 2×
“Concentrations to which cells are exposed in such cell metabolism studies should not cause perceptible cell death (Castell et al., 1997b).”
BackgroundSelf-citationPonsoda, X., Pareja, E., Gómez‐Lechón, M. J., Fabra, R., Carrasco, E., Trullenque, R., & Castell, J. V. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00085-4 · Cited by 44 · cited 3×
“Several studies show that primary hepatocyte cultures are a good model to qualitatively predict the in vivo metabolic profile of a drug (Bort et al., 1996a,b; Hewittt et al., 2001; Ponsoda et al., 2001; Salonen et al., 2003).”
BackgroundMethodSelf-citationCryopreserved porcine hepatocyte cultures
Koebe, H. G., Mühling, B., Deglmann, C. J., & Schildberg, F. W. (1999) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(99)00093-9 · Cited by 43 · cited 1×
“This is a method that was previously used by Koebe et al. (1996, 1999) to cryo-preserve porcine hepatocytes but they used a double gel sandwich culture.”
MethodXenobiotic lipids: The inclusion of xenobiotic compounds in pathways of lipid biosynthesis
Dodds, P. F. (1995) · Progress in Lipid Research · doi:10.1016/0163-7827(95)00007-m · Cited by 42 · cited 2×
“…several studies have shown that xenobiotic carboxylic acids, e.g., fenbufen and ibuprofen, can be incorporated into complex lipids, thus prolonging the time the drug stays in the body and potentially causing adverse effects through inhibition of lipid metabolizing enzymes, and so on (Dodds, 1995).”
BackgroundChieli, E., Santoni‐Rugiu, E., Cervelli, F., Sabbatini, A. R. M., Petrini, M., Romiti, N., Paolicchi, A., & Tongiani, R. (1994) · Carcinogenesis · doi:10.1093/carcin/15.2.335 · Cited by 42 · cited 1×
“The observed increase in mdr1 expression over time in primary hepatocytes is also reported by Fardel et al. (1993) and Chieli et al. (1994).”
BackgroundAccelerated Cytotoxicity Mechanism Screening Using Drug Metabolising Enzyme Modulators
O'Brien, P. J., & Siraki, A. G. (2005) · Current Drug Metabolism · doi:10.2174/1389200053586082 · Cited by 42 · cited 1×
“A particular advantage of suspensions over cultures is that metabolic capability is well preserved allowing for estimating and ranking the ability of compounds to cause marked cell necrosis mediated by metabolism (O’Brien and Siraki, 2005).”
BackgroundKuroha, M., Kuze, Y., Shimoda, M., & KOKUE, E. (2002) · American Journal of Veterinary Research · doi:10.2460/ajvr.2002.63.900 · Cited by 42
Pichard‐Garcia, L., Hyland, R., Baulieu, J., Fabre, J., Milton, A., & Maurel, P. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15002-7 · Cited by 41
Self-citationEffect of alpha-fluorination of valproic acid on valproyl-S-acyl-CoA formation in vivo in rats.
Grillo, M. P., Chiellini, G., Tonelli, M., & Benet, L. Z. (2001) · PubMed · Cited by 41
Human Hepatic Cell Cultures: In Vitro and In Vivo Drug Metabolism
Gómez-Lechón, M. J., Donato, M. T., Ponsoda, X., & Castell, J. V. (2003) · Alternatives to Laboratory Animals · doi:10.1177/026119290303100307 · Cited by 40 · cited 2×
“Drug metabolism and drug transport are major determinants of drug clearance, interindividual pharmacokinetic differences, clinical efficacy, and toxicity of drugs (Gomez-Lechón et al., 2003; Lu, 1998).”
BackgroundSelf-citationZhang, Y., & Benet, L. Z. (1998) · Pharmaceutical Research · doi:10.1023/a:1011990730230 · Cited by 40 · cited 1×
“One example is MDCK-MDR1 cells that are commonly used within drug industry to screen for MDR1 substrates and inhibitors (Zhang and Benet, 1998).”
BackgroundBort, R., Ponsoda, X., Carrasco, E., Gómez‐Lechón, M. J., & Castell, J. V. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07491-4 · Cited by 39 · cited 3×
“Several studies show that primary hepatocyte cultures are a good model to qualitatively predict the in vivo metabolic profile of a drug (Bort et al., 1996a,b; Hewittt et al., 2001; Ponsoda et al., 2001; Salonen et al., 2003).”
BackgroundSelf-citationThe acylation of proteins by xenobiotic amphipathic carboxylic acids in cultured rat hepatocytes
Hertz, R., & Bar‐Tana, J. (1988) · Biochemical Journal · doi:10.1042/bj2540039 · Cited by 38
Mechanistic basis of adverse drugreactions: the perils of inappropriate dose schedules
Shah, R. R. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.4.1.103 · Cited by 38 · cited 3×
“…them, changes in enzyme expression, as a consequence of induction or impairment of catalytic enzyme activities due to inhibitory effects of coadministered drugs, appear to be of major importance for the occurrence of adverse drug reactions or lack of therapeutic efficacy (Shah, 2005; Singh, 2006).”
BackgroundCRYOPRESERVED HUMAN HEPATOCYTES AS ALTERNATIVE IN VITRO MODEL FOR CYTOCHROME P450 INDUCTION STUDIES
Garcia, M., Rager, J. D., Wang, Q., Strab, R., Hidalgo, I. J., Owen, A. J., & Li, J. (2003) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1290/1543-706x(2003)039<0283:chhaai>2.0.co;2 · Cited by 37 · cited 3×
“…liver extracellular matrix to improve the attachment of thawed cells (Moshage et al., 1988), while others improved attachment by co-culturing hepatocytes with rat liver epithelial cells (Fautrel et al., 1997) or removed dead cells by Percoll purification (Garcia et al., 2003; Skett et al., 1999).”
BackgroundLawrence, J. N., & Benford, D. (1991) · Toxicology in Vitro · doi:10.1016/0887-2333(91)90046-g · Cited by 36 · cited 1×
“Early reports demonstrated a limited attachment efficiency of human hepatocytes after thawing (Chesné and Guillouzo, 1988; Lawrence and Benford, 1991).”
BackgroundFautrel, A., Joly, B., Guyomard, C., & Guillouzo, A. (1997) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1997.8253 · Cited by 36 · cited 2×
“, 1988), while others improved attachment by co-culturing hepatocytes with rat liver epithelial cells (Fautrel et al., 1997) or removed dead cells by Percoll purification (Garcia et al.”
BackgroundSelf-citationEnzyme induction in cryopreserved human hepatocyte cultures
Kafert-Kasting, S., Aleksandrova, K., Barthold, M., Laube, B., FRIEDRICH, G. E., Arseniev, L., & Hengstler, J. G. (2006) · Toxicology · doi:10.1016/j.tox.2005.12.013 · Cited by 35 · cited 5×
“…human hepatocytes are similar to that in fresh hepatocytes (Li et al., 1999b), there are reports that some batches of cryo-preserved hepatocyte cultures tend to have lower activities than those reported in corresponding fresh hepatocytes (Kafert-Kasting et al., 2006; Roymans et al., 2004, 2005).”
BackgroundInfluentialSelf-citationMoshage, H. J., Rijntjes, P. J. M., Hafkenscheid, J. C. M., Roelofs, H. M. J., & Yap, S. H. (1988) · Journal of Hepatology · doi:10.1016/s0168-8278(88)80504-x · Cited by 35 · cited 2×
“Some have used culture plates coated with human liver extracellular matrix to improve the attachment of thawed cells (Moshage et al., 1988), while others improved attachment by co-culturing hepatocytes with rat liver epithelial cells (Fautrel et al.”
MethodMolecular Cloning, Expression, and Characterization of CYP2D17 from Cynomolgus Monkey Liver
Mankowski, D. C., Laddison, K. J., Christopherson, P. A., Ekins, S., Tweedie, D., & Lawton, M. P. (1999) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1999.1506 · Cited by 35
Favreau, L. V., Palamanda, J. R., Lin, C., & Nomeir, A. A. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15203-8 · Cited by 34 · cited 2×
“The inhibition of enzymes is easy to measure because the onset of the effect is normally rapid and reproducible in vitro by using recombinant enzymes, human liver microsomes (Favreau et al., 1999; Nomeir et al., 2001) or even hepatocytes (Zhao et al.”
BackgroundThe effects of dexamethasone on metabolic activity of hepatocytes in primary monolayer culture
YAMADA, S., Otto, P. S., Kennedy, D. L., & Whayne, T. F. (1980) · In Vitro Cellular & Developmental Biology - Plant · doi:10.1007/bf02618379 · Cited by 33 · cited 2×
“Once the cells are in culture, the addition of the glucocorticoid hormone, dexamethasone, is valuable for the long-term preservation of hepatocyte-specific functions, polygonal hepatocyte morphology, as well as the structural integrity of cytoplasmic membranes, especially bile canaliculi-like structures (Yamada et al.…”
BackgroundCoffman, B. L., Kearney, W. R., Green, M. D., Lowery, R. G., & Tephly, T. R. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.6.1464 · Cited by 32
Permissive and suppressive effects of dexamethasone on enzyme induction in hepatocyte co-cultures
Ringel, M. T., Oesch, F., Gerl, M., Klebach, M., Quint, M., Bader, A., Böttger, T., & Hengstler, J. G. (2002) · Xenobiotica · doi:10.1080/00498250210144811 · Cited by 32 · cited 2×
“Pretreatment of hepatocytes with low concentrations of dexamethasone (for example, 30 nM), does not cause increased expression of CYP3A or CYP2B per se but serves as a permissive factor allowing a stronger induction by enzyme inducers (Pascussi et al., 2001,2003; Ringel et al., 2002).”
BackgroundMethodSelf-citationHewitt, N. J., Lloyd, S., Hayden, M., Butler, R. K., Sakai, Y., Springer, R., Fackett, A., & Li, A. P. (2002) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(02)00055-8 · Cited by 32 · cited 1×
“Hewitt et al. (2002) showed that the cytotoxicity of troglitazone in cryo-preserved human hepatocytes from 27 different donors was correlated to CYP3A4 activities, together with the ratio of SULT and UGT activities.”
BackgroundSelf-citationMach, M., Hengstler, J. G., Brulport, M., Eberhardt, M., Schormann, W., Hermes, M., Prawitt, D., Zabel, B., Grosche, J., Reichenbach, A., et al. (2004) · Stem Cells · doi:10.1634/stemcells.2004-0061 · Cited by 30 · cited 1×
“…aimed at differentiating different human extra-hepatic stem cells to hepatocytes have been performed by a relatively large number of groups (Avital et al., 2001; Eberhardt et al., 2006; Fiegel et al., 2003; Lavon et al., 2004; Lee et al., 2004; von Mach et al., 2004; Zulewski et al., 2001).”
BackgroundSelf-citationPosti, K., Leinonen, S., Tetri, S., Kottari, S., Viitala, P., Pelkonen, O., & Raunio, H. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00539.x · Cited by 30
Metabolic Activity of Freshly Prepared and Cryopreserved Hepatocytes in Monolayer Culture
Loecker, P. D., Fuller, B. J., Koptelov, V. A., & Loecker, W. D. (1993) · Cryobiology · doi:10.1006/cryo.1993.1002 · Cited by 30 · cited 1×
“Another common method to reduce the osmotic effect of diluting DMSO was to slowly add small volumes of medium over a period of 10 min to allow DMSO to equilibrate between the medium and the intracellular environment (de Loecker et al., 1993; Li et al., 1999b).”
MethodMDMA toxicity: no evidence for a major influence of metabolic genotype at CYP2D6
O'Donohoe, A., O’Flynn, K., Shields, K. G., Hawi, Z., & Gill, M. (1998) · Addiction Biology · doi:10.1080/13556219872119 · Cited by 30 · cited 1×
“Some individuals have died after ingestion of a single tablet, while others have survived after high doses of MDMA, suffering only mild sympathetic symptoms such as tachycardia and hypertension (de Letter et al., 2004; O’Donohoe et al., 1998).”
BackgroundFisher, M. B., Yoon, K., Vaughn, M. L., Strelevitz, T. J., & Foti, R. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.10.1087 · Cited by 30 · cited 2×
“Almost all predictions for human clearance are made using 120 million cells/g liver weight (Andersson et al., 2001; Bachmann et al., 2003; Bayliss et al., 1999; Davies and Morris 1993; Fisher et al., 2002; Iwatsubo et al., 1997; Lave et al., 1997; McGinnity et al., 2004; Naritomi et al., 2003; Salonen et al., 2003; So…”
BackgroundMethodReichard, J. F., Doorn, J. A., Simon, F., Taylor, M. S., & Petersen, D. R. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(03)00002-x · Cited by 28 · cited 2×
“…cultures (either as a conventional monolayer with no overlay or as a sandwich culture (Liu et al., 1999; Rose et al., 2006)), primary hepatocyte suspensions (Reichard et al., 2003; Sandker et al., 1994) and transfected cell lines expressing defined transporters (Biermann et al., 2006; Sahi, 2005).”
BackgroundDetoxification Strategy of Epoxide Hydrolase The Basis for a Threshold in Chemical Carcinogenesis
Arand, M., Plana, M. E. H., Hengstler, J. G., Lohmann, M., Cronin, A., & Oesch, F. (2003) · Cited by 28
Self-citationETHYNYLESTRADIOL INCREASES EXPRESSION AND ACTIVITY OF RAT LIVER MRP3
Ruiz, M. L., Villanueva, S. S. M., Luquita, M. G., Vore, M. E., Mottino, A. D., & Catania, V. A. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.009316 · Cited by 28 · cited 2×
“…ex-vivo or in vitro models are available for exploring the contribution of transporters to drug metabolism and excretion, including liver perfusion (Ruiz et al., 2006), liver slices (Elferink et al., 2004; Olinga et al., 2001), primary hepatocyte cultures (either as a conventional monolayer with…”
BackgroundOlinga, P., Merema, M. T., Hof, I. H., Slooff, M. J. H., Proost, J. H., Meijer, D. K. F., & Groothuis, G. M. M. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37452-x · Cited by 27 · cited 2×
“While for rat hepatocytes, this is usually not a very big issue because, unlike human hepatocytes, hepatocytes from a single rat strain should not vary significantly (Olinga et al., 1998a; Richert et al., 2004).”
BackgroundSelf-citationActivation of Carcinogens by Human Liver Cytochromes P-450
Guengerich, F. P., Shimada, T., Iwasaki, M., Butler, M. A., & Kadlubar, F. F. (1990) · Springer eBooks · doi:10.1007/978-1-4613-0637-5_30 · Cited by 26 · cited 2×
“, 2002), however, it is involved in the bioactivation of pro-carcinogens and is therefore considered to be an important enzyme to test (Guengerich et al., 1990).”
BackgroundUse ofin vitrotransporter assays to understand hepatic and renal disposition of new drug candidates
Sahi, J. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.3.409 · Cited by 25 · cited 7×
“The OATPs, OATs, and OCTs are essentially bidirectional transporters and although they usually function as uptake carrier, they may also serve as sinusoidal excretion carrier, dependent on conditions such as substrate concentration gradients and other driving forces.”
BackgroundMethodInfluentialMDMA: fact and fallacy, and the need to increase knowledge in both the scientific and popular press
Green, A. R. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1820-z · Cited by 24 · cited 1×
“However, despite its widespread use, the number of MDMA-related deaths and severe intoxications is relatively low (Green, 2004), therefore, MDMA is commonly misrepresented among its users as being safe.”
BackgroundTerry, T. L., & Gallin, W. J. (1994) · Experimental Cell Research · doi:10.1006/excr.1994.1302 · Cited by 24 · cited 1×
“This is consistent with the findings of Terry and Gallin (1994) who reported that serum is capable of inhibiting the re-establishment of bile canaliculi in hepatocyte cultures.”
ResultGalisteo, M., Marc, N., Fautrel, A., Guillouzo, A., Corcos, L., & Lagadic‐Gossmann, D. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35031-1 · Cited by 21
Self-citationWahlström, A., Persson, K., & Rane, A. (1989) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08747-1 · Cited by 20 · cited 1×
“Naloxone is glucuronidated by UG2B7 (Coffman et al., 2001; Wahlstrom et al., 1989) and was compared to hydroxycoumarin glucuronidation, which is conjugated by UGT1A6 (Lampe et al., 1999) so a correlation would not be expected.”
BackgroundLieu, Y. K., Hsu, B. Y. L., Price, W. A., Corkey, B. E., & Stanley, C. A. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.272.3.e359 · Cited by 20 · cited 1×
“The hypoglycin metabolite, methylenecyclopropylacetate-CoA, is known to inhibit β-oxidation of fatty acids by suicide-inhibition of multiple acyl-CoA dehydrogenase enzymes in mitochondria (Lieu et al., 1997; Wenz et al., 1981).”
BackgroundSkett, P., Roberts, P. T. E., & Khan, S. (1999) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(99)00091-5 · Cited by 19 · cited 3×
“Cryo-preserved hepatocytes with high viabilities and good metabolic capacities have been reported (Chesne and Guillouzo, 1988; Hewitt et al., 2001; Kafert-Kasting et al., 2006; Li et al.; 1999b; Silva et al., 1999; Skett et al., 1999).”
BackgroundJones, H. M., Hallifax, D., & Houston, J. B. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.5.572 · Cited by 19 · cited 1×
“The relationship between fuinc, Kp and the volume ratio (VR) of the cell to the total incubation (Jones et al., 2004) is summarized in Eq.”
BackgroundSelf-citationSteube, K. G., Meyer, C., Uphoff, C. C., & Drexler, H. G. (2003) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1290/0308057 · Cited by 18
Baillie, T. A., Kassahun, K., Grillo, M. P., Hu, P. L., Shirley, M. A., Lin, J., & Lévy, R. H. (1992) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp.1992.3.s1.68 · Cited by 16
Transduction of Immortalized Human Hepatocytes with p21 to Enhance Differentiated Phenotypes
Kunieda, T., Kobayashi, N., Sakaguchi, M., Okitsu, T., Totsugawa, T., Watanabe, T., Matsumura, T., Maruyama, M., Noguchi, H., Takesue, M., et al. (2002) · Cell Transplantation · doi:10.3727/000000002783985666 · Cited by 16 · cited 1×
“Cells that had been infected with p21 showed differentiated hepatic phenotypes in morphology and increased CYP3A4 and CYP2C9 protein expression (Kobayashi et al., 2002a; Kunieda et al., 2002).”
BackgroundHarauchi, T., & HIRATA, M. (1994) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.17.658 · Cited by 14
Hepatobiliary Disposition in Primary Cultures of Dog and Monkey Hepatocytes
Rose, K., Kostrubsky, V. E., & Sahi, J. (2006) · Molecular Pharmaceutics · doi:10.1021/mp0501022 · Cited by 13 · cited 2×
“, 2001), primary hepatocyte cultures (either as a conventional monolayer with no overlay or as a sandwich culture (Liu et al., 1999; Rose et al., 2006)), primary hepatocyte suspensions (Reichard et al.”
BackgroundAlexander, J. J. (1987) · Springer eBooks · doi:10.1007/978-4-431-68349-0_4 · Cited by 11
Omeprazole and aryl hydrocarbon hydroxylases: Should we be worried?
Kolars, J. C., Turgeon, D. K., & Watkins, P. B. (1991) · Hepatology · doi:10.1002/hep.1840130131 · Cited by 11 · cited 1×
“Like inhibition, induction results in altered pharmacokinetics or pharmacodynamics (Dilger et al., 2000; Kolars et al., 1991).”
BackgroundImpact of end-product inhibition on the determination ofin vitrometabolic clearance
Jones, H. M., Nicholls, G., & Houston, J. B. (2005) · Xenobiotica · doi:10.1080/00498250500136619 · Cited by 10 · cited 1×
“There may be product accumulation due to loss of sequential metabolism and this may result in a possible feedback inhibition effect (Jones et al., 2005).”
BackgroundSelf-citationLee, C. H. (2002) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10207 · Cited by 10 · cited 1×
“The increase in MDR1 expression over time is less pronounced in sandwich cultures, which is in agreement with Lee (2002).”
ResultXenobiotic metabolism in epithelial cell cultures
Guillouzo, A., & Chesné, C. (1996) · doi:10.1093/oso/9780199635733.003.0004 · Cited by 10
Self-citationSchuppe‐Koistinen, I., Frisk, A.-L., & Janzon, L. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00355-4 · Cited by 9
Kobayashi, N., Sakaguchi, M., Okitsu, T., Totsugawa, T., Maruyama, M., Matsumura, T., Watanabe, T., Noguchi, H., Kosaka, Y., Fujiwara, T., et al. (2002) · ASAIO Journal · doi:10.1097/00002480-200207000-00005 · Cited by 7
Postulated Reactive Intermediates of NSAID’s
Drew, R., & Knights, K. (1985) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7720-6_15 · Cited by 6 · cited 1×
“Recently, interest has turned to acyl-CoAs as chemically reactive metabolites, although speculations on sources of reactive metabolites other than acyl-glucuronides already arose in the 1980s (Drew and Knights, 1985; Hertz and Bar-Tana, 1998; Stogniew and Fenselau, 1982).”
BackgroundMeijer, D. K. F., & van Montfoort, J. E. (2002) · Archives of Pharmacal Research · doi:10.1007/bf02976592 · Cited by 5
Research works printed but not linked: 48
- Allen S. W., 2001, Drug Metab. Dispos., 29, 1074
- Andersson T. B., 2001, Drug Metab. Dispos., 29, 712
- Arand M., 2003, EXCLI J., 22, 22
- 10.1177/0091270003252519 · doi:10.1177/0091270003252519 · Paper page
- Bort R., 1996, Drug Metab. Dispos., 24, 834
- Bort R., 1996, Drug Metab. Dispos., 24, 969
- Brown H. S., 2006, Drug metab. Dispos., 200, 6
- Chauret N., 1998, Drug Metab. Dispos., 26, 1
- Code E. L., 1997, Drug Metab. Dispos., 25, 985
- Cui Y., 2001, Mol. Pharmacol., 60, 934, 10.1124/mol.60.5.934 · doi:10.1124/mol.60.5.934 · Paper page
- Curi-Pedrosa R., 1994, J. Pharmacol. Exp. Ther., 269, 384
- Donato M. T., 1995, Drug Metab. Disp., 23, 553
- Drew R., 1985, Agents Actions Suppl., 17, 127
- Drocourt L., 2001, Drug Metab. Dispos., 29, 1325
- Easterbrook J., 2001, Drug Metab. Dispos., 29, 141
- Elferink M. G., 2004, Physiol., 287, G1008
- Eneroth A., 2006, Drug Metab. Rev., 38, 61
- Gerbal-Chaloin S., 2001, Drug Metab. Dispos., 29, 242
- Goodwin B., 1999, Mol. Pharmacol., 56, 1329, 10.1124/mol.56.6.1329 · doi:10.1124/mol.56.6.1329 · Paper page
- Grillo M. P., 2001, Drug Metab. Dispos., 29, 1210
- Guengerich F. P, 1990, Basic Life Sci., 53, 381
- Hallifax D., 2006, Drug Metab. Dispos.
- 10.1517/17425255.1.1.61 · DOI · Paper page
- Hewitt N. J., 2001, Drug Metab. Dispos., 29, 1042
- Hewitt N. J., Chem. Biol. Interact.
- Hickman D., 1998, Drug Metab. Dispos., 26, 207
- Hopwood J., 2004, Toxicology, 202, 103
- Klingmüller U., 2006, Systems Biology
- Koganti A., 2005, Drug Metab. Rev., 37, 212
- Kolars J. C., 1991, Hepatology, 13, 197
- Lieu Y. K., 1997, Am. J. Physiol., 272, E359
- 10.1016/j.cbi.2004.09.010 · DOI
- Liu X., 1999, Am. J. Physiol., 277, G12
- Lu A. Y. H, 1998, Drug Metab. Dispos., 26, 1217
- Nomeir A. A., 2001, Drug Metab. Dispos., 29, 748
- Nussler A., 2006, J. Hepatol., 200, 6
- Olinga P., 1998, Drug Metab. Dispos., 26, 5
- Parkinson A, 2001, Casserett and Doull's Toxicology. The Basic Science of Poisons 6th, 133
- Pascussi J. M., 2000, Mol. Pharmacol., 58, 361, 10.1124/mol.58.2.361 · doi:10.1124/mol.58.2.361 · Paper page
- Pascussi J. M., 2000, Mol. Pharmacol., 58, 1441, 10.1124/mol.58.6.1441 · doi:10.1124/mol.58.6.1441 · Paper page
- Ruegg C. E., 1997, In Vitro Technol., 10, 217
- Ruhnke M., 2005, Gastroenterology
- Shimada T., 1994, J. Pharmacol. Exp. Ther., 270, 414
- Stogniew M., 1982, Drug Metab. Dispos., 10, 609
- van Breemen R. B., 1985, Drug Metab. Dispos., 13, 318
- Wahlstrom A., 1989, Drug Metab. Dispos., 17, 218
- Wenz A., 1981, J. Biol. Chem., 256, 9809, 10.1016/S0021-9258(19)68697-7 · DOI
- Zimmerman H. J, 1994, Nonsteroidal Anti-Inflammatory Drugs: Mechanisms and Clinical Uses 2nd
Cited by
The Many Roles for Fluorine in Medicinal Chemistry
Hagmann, W. K. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800219f · Cited by 3,578
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
“In 2007, a review on the ‘‘current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies’’ was published (Hewitt et al. 2007).”
Self-citationMicroscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219
Deterministically patterned biomimetic human iPSC-derived hepatic model via rapid 3D bioprinting
Ma, X., Qu, X., Zhu, W., Li, Y.-S., Yuan, S., Zhang, H., Liu, J., Wang, P., Lai, C. S. E., Zanella, F., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524510113 · Cited by 872
“The complex microarchitecture and cellular interactions in liver are thought to be essential to long-term hepatocyte functional maintenance as supported by many reports on the loss of liver-specific functions from hepatocytes taken out from the liver (5, 6).”
BackgroundBell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25187 · Cited by 739
Metadata
- Authors
- Hewitt, N. J., Gómez Lechón, M. J., Houston, J. B., Hallifax, D., Brown, H. S., Maurel, P., Kenna, J. G., Gustavsson, L., Lohmann, C., Skonberg, C., Guillouzo, A., Tuschl, G., Li, A. P., LeCluyse, E., Groothuis, G. M. M., & Hengstler, J. G.
- Affiliations
- University of Manchester (GB)
- Inserm (FR)
- AstraZeneca (Sweden) (SE)
- Merck KGaA, Darmstadt (Germany) (DE)
- University of Groningen (NL)
- Leipzig University (DE)
- ORCID
- Venue
- Drug Metabolism Reviews
- Publisher
- Informa UK Limited
- Published
- 2007-01
- Volume
- 39
- Issue
- 1
- Pages
- 159-234
- ISSN
- 0360-2532 (ISSN-L)
- 1097-9883
- OpenAlex
- W2171534546
- Cited by
- 735
- References
- 352
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 18 · 2023: 17 · 2022: 15 · 2021: 32 · 2020: 33 · 2019: 28 · 2018: 38 · 2017: 31 · 2016: 44 · 2015: 51 · 2014: 55 · 2013: 53 · 2012: 71
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Metabolism Reviews (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- primary human hepatocytes, drug metabolism, drug transporters, drug clearance, in vitro-in vivo correlation, idiosyncratic hepatotoxicity, drug development
- MeSH terms
- Animals, Carrier Proteins, Cytochrome P-450 Enzyme System, Pharmaceutical Preparations, Humans, Liver Diseases, Metabolic Clearance Rate, Models, Biological, Xenobiotics, Hepatocytes, Chemical and Drug Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.